Skip to content
St Vincent's Centre for Applied Medical Research

David Ma

Professor David Ma is the Director of Research for the Haematology AMR Research Program at St Vincent’s Centre for Applied Medical Research.

Avatar for Research Program

Research Program: Haematology Laboratory Research Program

Haematology Laboratory Research Program

Bio

Professor David Ma is the Director of Research for the Haematology AMR Research Program at St Vincent’s Centre for Applied Medical Research. His translational research has led to improvements in standards of care for transplantation, immunotherapy and targeted therapeutics. This includes the 2025 launch of the Royal College of Pathologists of Australasia QAP program for transplantation, a world first. Prof Ma was invited to work with the drug discovery team of Johnson & Johnson in 2003. In 2006, he played a critical role in designing and executing the world first clinical trial of HSC gene therapy in HIV (published 2009). Professor Ma was the first to discover multidrug resistance P glycoprotein in human acute leukaemia and recent drug discovery research led to a patent in 2019. He is a Conjoint Professor at UNSW Sydney and has ~200 publications (Scopus citations total 10,188 and H-index 45, including JCO, Nature Medicine and Lancet).
David Ma

PublicationsSelected Publications from David Ma

  • Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors. Ma DD, Liu Z, Au K, et al. J Clin Oncol. 2025; 10;43(8):949-959. DOI: 10.1200/JCO.24.00333. PMID: 39591546.
  • miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia. Vu TT, Stölzel F, Wang KW, et al. Leukemia. 2021; 35(7):1933-48. DOI: 10.1038/s41375-020-01095-z. PMID: 33262524.
  • Direct comparison of four strategies for hematopoietic differentiation from human induced pluripotent stem cells. Tursky ML, Loi TH, Artuz CM, et al. Stem Cell Reports. 2020; 15(3): 735-748. DOI: 10.1016/j.stemcr.2020.07.009. PMID: 32763163.
  • Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Mitsuyasu RT, Merigan T, Carr AD, et al. Nature Medicine. 2009; 15(3):285-92. DOI: 10.1038/nm.1932. PMID: 19219022.
  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Pfreundschuh M, Trumper L, Osterborg A, et al. Lancet Oncology. 2006;7(5):379-442. DOI: 10.1016/S1470-2045(06)70664-7. PMID: 16648042.